FDA Approves TRULICITY — Eli Lilly and Company

# FDA Approves Eli Lilly's Trulicity for Type 2 Diabetes Treatment Eli Lilly and Company received FDA approval for Trulicity (dulaglutide), a once-weekly subcutaneous GLP-1 receptor agonist, positioning the company to compete in the rapidly expanding diabetes market against established players like Novo Nordisk's Victoza. The approval marks a significant addition to Eli Lilly's diabetes portfolio and opens substantial commercial opportunities as healthcare providers increasingly adopt modern injectable therapies for glycemic control.